Commercialization: Page 41
-
Patient Advocates
Dr. Stella Blackburn Title: VP, Global Head of Risk Management, Real World & Late Phase Research Company: Quintiles Education: M.B., B.S., Medicine, Guy’s Hospital Med School, London University; M.Sc., Epidemiology, London School of Hygiene and Tropical Medicine, U. of London; M.A., Medical S...
By PharmaVoice Team • Aug. 1, 2015 -
Red Jacket Awards
Jeff Aronin TITLE: Founder, Chairman, and CEO COMPANY: Marathon Pharmaceuticals LLC ASSOCIATIONS: University of Chicago Medical Center, Board Member Museum of Science & Industry, Board Member Aspen Institute, Henry Crown Fellow, Member Economic Club, Board Member Commercial AWARDS/HONORS: Bra...
By PharmaVoice Team • Aug. 1, 2015 -
Fun Facts About the PharmaVOICE 100
Where they were born? The PharmaVOICE 100 may come from all over, but what they have in common is a sincere desire to improve the lives of patients everywhere. What was their first job? We thought it would be fun to know how these highly successful executives earned their first paychecks. As it t...
By PharmaVoice Team • Aug. 1, 2015 -
The Importance of Mentoring
Most of our PharmaVOICE 100 honorees say having and being a mentor are important for success in this industry. Here is what they say about the value of being a mentor to others. Sound Bites from the PharmaVOICE 100 Our honorees talk about the importance of mentoring. David Baker Chief Commercial ...
By PharmaVoice Team • Aug. 1, 2015 -
Overcoming the Challenges that Hinder Innovation
PharmaVOICE 100 honorees discuss the challenges that the industry needs to overcome to support future innovation. Between 2009 and 2014, the annual growth rate for the top 25 life-sciences companies slowed from the prior decade’s double-digit average to only 1% annually, according to a recent rep...
By PharmaVoice Team • Aug. 1, 2015 -
Innovation In a Patient-Centric World
From healthcare reform to the push for value in medicines to personalized healthcare, the patient is now at the center of, well, everything. This means that pharmaceutical companies are now required to create a new paradigm, with the patient at the center. An initiative that began last year withi...
By PharmaVoice Team • Aug. 1, 2015 -
Letter from the Editor
In the rare disease community there is saying: Alone we are rare, together we are strong. Wendy White, senior VP, for rare diseases, at Dohmen Life Science Services, a board member of Global Genes, and the president of the Heathcare Businesswomen’s Association (HBA), shared her personal rare dis...
By Taren Grom • June 1, 2015 -
What's New
Medicines360 is Driven to Empower Women Trending now: New nonprofit pharma company changing access to medicine. San Francisco-based Medicines360.org is a nonprofit pharma company that is doing things differently from traditional pharma companies. Its mission is to help remove barriers and improv...
By PharmaVoice Team • June 1, 2015 -
Tools of the Trade
N-of-One Launches App Sequencing Data Trending Now: As the life-sciences business continues to diversify across borders and new channels, the need for easily accessible and accurate HCO, HCP, and affiliation information has never been greater. N-of-One has launched Variant Interpreter, a cloud-ba...
By PharmaVoice Team • June 1, 2015 -
Pharma Trax
Uptake of Digital Records Not sufficient to Drive Better Care Trending now: Despite increased use of electronic medical records, fewer U.S. doctors believe it improves health outcomes. Most U.S. doctors are more proficient using electronic medical records (EMR) than they were two years ago, but f...
By PharmaVoice Team • June 1, 2015 -
Talent Pool
Biopharma Pool David Allsop Amicus Therapeutics Appoints Senior VP, International Amicus Therapeutics, a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, has appointed David Allsop as senior VP, international. He is responsible for Amicus’ international organi...
By PharmaVoice Team • June 1, 2015 -
Patient Engagement: Not Just For Physicians Anymore
When Pfizer wanted to engage with people living with chronic pain, it used an online crowdsourcing model and social media campaign that connected thousands of people, from patients and caregivers, to nurses and doctors. In what was the first initiative of its kind by a pharmaceutical company, Pfi...
By Robin Robinson • June 1, 2015 -
C-Suite: Digital Agencies
Digital Agencies C-suite executives from some of the industry’s leading digital agencies provide their insights on where the greatest opportunities for innovation lie to improve digital marketing, the greatest challenges involved with digital media, and best practices for reaching stakeholders ...
By PharmaVoice Team • June 1, 2015 -
Endpoint-Based Protocol Development: An Outcomes-Based Approach to Clinical Trial Testing
A shift toward more targeted therapeutics, combined with the need to meet specific endpoints in clinical trials, has placed a significant emphasis on esoteric laboratory tests within the test menus employed in clinical trials. Biopharmaceutical companies and clinical research organizations have l...
By Mark Engelhart • June 1, 2015 -
Patient or Partner? Building An Innovative Relationship for the Future
The healthcare industry has struggled with many changes in the last 10 years, including the inevitable patent cliff, the emergence of patient advocacy, increased regulatory and healthcare reform, and the rising cost of doing business. However, even in this age of rapid innovation and adaptability...
By Marc Sirockman • June 1, 2015 -
How Do iComply? A Look at Regulatory Topics Surrounding the use of Mhealth Technology in Clinical Trials
The U.S. National Institutes of Health (NIH) Consensus Group has defined mHealth as “the use of mobile and wireless devices to improve health outcomes, health care services and health research." The mHealth landscape is expanding with over 97,000 apps (mobile applications) as of 2013. Yet the vas...
By Philip Coran • June 1, 2015 -
Extracting Maximum Value From Electronic Data Capture
Electronic data capture (EDC) has been employed for clinical trial data for many years and is encouraged by the FDA because it provides significant benefits to sponsors, investigators, and patients, including more accurate data that can be more easily shared and monitored, increased compliance wi...
By Zaher El-Assi • June 1, 2015 -
Which Patients Are Really at Risk For Becoming Non-Adherent?
If you’re targeting only the most obvious patients with your medication adherence programs, you’re missing out on a big opportunity. Quite often, outreach programs focus on individuals hovering around the 80% threshold for proportion of days covered (PDC). It makes sense. Why not use your resourc...
By Craig Schilling • June 1, 2015 -
Seeing the Big Picture With Visual Data Analytics
Pharmaceutical and biotechnology companies are facing a gigantic increase in data — not just in volume, but in complexity. The number of clinical trials in the National Institute of Health’s registry has jumped from 5,635 in 2000 to 183,991 in 2015 — an increase of more than 30 times. The data la...
By Greg Moody • June 1, 2015 -
Five Tips for Expediting Clinical Trial Recruitment and Enhancing Patient Retention
According to the National Institutes of Health (NIH), more than 80% of clinical trials in the United States fail to meet their patient recruitment timelines. These delays increase costs, deplete resources, and prolong the time to market introduction. Patient recruitment is challenging as it invol...
By Lou Shapiro • June 1, 2015 -
Everything You Wanted to Know About Pharmacovigilance But Have Been Afraid to Ask
From the time humans begin taking an investigational new drug, pharmacovigilance measures play a critical role in every phase of a product’s lifecycle. However, understanding pharmacovigilance requirements can be daunting even for seasoned industry pros. This overview will answer all the question...
By Veronique Basch • June 1, 2015 -
Letter from the Editor
In this month’s Forum, experts from multiple disciplines, from drug development to marketing, discuss the challenges and opportunities that technology is bringing to the table. AstraZeneca’s CIO David Smoley sums up the changing landscape neatly: “When it comes to IT, we cannot operate in a world...
By Taren Grom • May 1, 2015 -
On the Calendar
Coming Attractions DIA 2015, the 51st annual meeting, is the largest multidisciplinary event that brings together a global network of life-sciences professionals to foster innovation that will lead to the development of safe and effective medical products and therapies to patients. This year’s t...
By PharmaVoice Team • May 1, 2015 -
Talent Pool
Biopharma Pool Steven Ertel Dr. Matthew Sherman Acceleron Pharma Announces Executive Appointments and Promotions Acceleron Pharma, a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic candidates that regulate cellular growth...
By PharmaVoice Team • May 1, 2015 -
A 21st Century CEO Challenge: Technology
AstraZeneca made a bold move last year and took back control of its servers and networks that pertained to core drug development from outsourcing vendors, which led to a 90% reduction in the number of critical outages, and decreased incident response down to a few hours instead of several days. F...
By PharmaVoice Team • May 1, 2015